Want Ivermectin For COVID-19 Treatment? The UF Health study may be for you


The University of Florida Health is looking for up to 200 people willing to participate in a national study to determine whether three currently available over-the-counter drugs can help people manage symptoms of COVID-19 and prevent hospitalizations.

Initially, the university and A clinical research network in Florida + study the effectiveness of fluticasone, an inhaled steroid commonly used to treat asthma and chronic obstructive pulmonary disease; fluvoxamine, a medicine prescribed to treat depression; and ivermectin, an antiparasitic medicine in pill form prescribed to treat people with infections caused by certain parasitic worms.

Some people have started using the veterinary form of ivermectin, although there is no strong clinical evidence that it works. Not worth anything: The ivermectin tested in the ACTIV-6 study is a form of the drug approved by the FDA for use in humans.

Study volunteers must be at least 30 years old, have tested positive for COVID-19, and have suffered, for less than seven days, from two or more mild symptoms of COVID-19. Symptoms of COVID-19 can include fatigue, shortness of breath, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal congestion, or loss of sense of taste. The university hopes to enroll people of color who have been disproportionately affected by the virus, as well as those who live in rural areas, for the study.

The study is one of several nationwide research projects that are part of the Accelerate therapeutic interventions and COVID-19 vaccines, or ACTIV, public-private partnership funded by the National Institutes of Health. In total, researchers hope to enroll 15,000 participants across the country.

UF Health will participate in the ACTIV-6 study, which explores the effectiveness of drugs approved by the United States Food and Drug Administration for other conditions for COVID-19.

Elizabeth A. Shenkmam, president of the Department of Health Outcomes and Biomedical Informatics from UF College of Medicine and co-principal investigator of the OneFlorida + Clinical Research Network, said the goal is to identify drugs that can help people feel better faster and keep them from getting better. go to the hospital.

Shenkman is the UF Health site principal investigator for ACTIV-6. Christina li, an assistant professor in the division of internal medicine at UF College of Medicine, is the principal investigator of the UF Health physicians site.

The drugs the researchers will test have already been shown, in preliminary studies, to be somewhat effective against the COVID-19 virus, Shenkman said in a prepared statement announcing the study.

“The only way to confirm that these drugs are safe and effective in treating the symptoms of COVID-19 is to conduct a large controlled clinical research study,” Shenkman said. “We hope that ACTIV-6 will provide scientifically rigorous and definitive results.”

Participants will be randomly assigned to receive either a placebo or one of three over-the-counter drugs under study. Participants will be asked to record their symptoms in diaries and answer questionnaires online or over the phone. Participants will receive over-the-counter drug shipments to their homes.

Study participants will also be asked if they have long-term symptoms of COVID-19 three months after the study begins.

The researchers, meanwhile, will monitor hospitalizations and deaths of participants over a 28-day period.

The Duke Clinical Research Institute in Durham, North Carolina, serves as the study’s clinical coordinating center, partnering with Vanderbilt University Medical Center in Nashville, Tennessee, as the study’s data coordinating center.

For more information, visit the ACTIV-6 study website.


Views of the publication:
73


Comments are closed.